Truist Lowers DexCom (DXCM) PT to $94 Ahead of Q3 MedTech Sector Preview, Maintains Buy Rating

DexCom Inc. (NASDAQ:DXCM) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 15, Truist analyst Richard Newitter lowered the firm’s price target on DexCom to $94 from $102 with a Buy rating on the shares as part of the firm’s broader research note previewing Q3 2025 results in the MedTech sector. The firm anticipates healthy revenue and earnings for Q3 across all companies it covers, but warns of stock volatility. Truist Lowers DexCom (DXCM) PT to $94 Ahead of Q3 MedTech Secto ...